• Publications
• Experience
• About

Professional Focus

Dr. Roach is recognized as a major authority on the treatment of clinically localized prostate cancer. He served as lead author for the 1996, 2000 and pending 2006 editions of the American College of Radiology Appropriateness Criteria Guidelines for defining how men in this country should be simulated and treated with radiotherapy. He also served on the NCI Intensity Modulated Radiotherapy Working Group to define jargon and criteria for defining the use of this new technology. He helped co-author the 2001 prostate cancer screening guidelines put forth by the American Cancer Society. He is best known for the recently completed prospective randomized RTOG trial that demonstrated the value of pelvic nodal radiotherapy for patients with high risk prostate cancer.

Education

1975	Morehouse College, Atlanta, GA	BS (Honors)	Physics
1979	Stanford University School of Medicine	MD
1979-1981	Martin Luther King, Jr., General Hospital, Los Angeles, CA	Internship and Resident
1981-1983	UCSF	Fellow	Hematology-Oncology
1983-1984	Highland General Hospital, Oakland, CA	Chief Resident	Medicine
1984-1987	Stanford University School of Medicine	Resident	Radiation Therapy (Chief Resident - 1986)

Professional Experience

2007-present	UCSF	Professor & Chair	Radiation Oncology
2006-2007	UCSF	Professor & Interim Chair	Radiation Oncology
2003-2006	UCSF	Professor & Vice Chair	Radiation Oncology
2003-present	UCSF	Professor	Urology
2001-present	UCSF	Director, Clinical Research	Radiation Oncology
2000-2003	UCSF	Professor in Residence	Radiation Oncology & Urology
1997-2000	UCSF	Associate Professor	Urology
1994-2000	UCSF	Associate Professor in Residence	Radiation Oncology & Medical Oncology
1990-1994	UCSF	Assistant Professor in Residence	Radiation Oncology
1988-1990	Veterans Administration Medical Center, Martinez, CA	Chief	Radiation Oncology
Services
1987-1988	Veterans Administration Medical Center, Martinez, CA	Acting Chief	Radiation Oncology Services

Awards & Honors

1979-1980	Outstanding Intern of the Year (Charles R. Drew Award)
1981-1982	Fellow, American Cancer Society
1994-1997	American Cancer Society, Career Development Award
1994	UCSF Health Net Wellness Award
1996-1997	Best Doctors in America ®
1997, 1998	Best Doctors in the Bay Area
1999	Health & Wellness Award - 100 Black Men of the Bay Area Inc.
2001-2002	Best Doctors in America ®
2002	Fellow, American College of Radiology
2002-2003	President, John Hale Medical Society
2003-2004	Best Doctors in America ®
2005	10 Most Influential African Americans in the Bay Area (Healthcare)
2005-2006	Best Doctors in America ®
2007	UCSF Award for Community Service
2007-2008	The Best Doctors in America ®
2008	Bennie Service Award, Morehouse College

Publications - Partial Listing since 2000

Wilder, R. B., R. H. Chou, Ryu, J.K., Leigh, B.R., Earle, J.D., Doggett, R.L., Kubo, H.D., Roach, M., 3^rd, deVere White, R.W. Potency preservation after three-dimensional conformal radiotherapy for prostate cancer - Preliminary results. Am J of Cl Oncol-Cancer Clinical Trials 23 (4): 330-333, 2000.

Young, C.D., Roach, M., 3^rd, Race and Prostate Cancer: What Do We Know? The Prostate Journal 2(1): 33-41, 2000.

Hsu, I.C., Pickett, B., Shinohara, K., Krieg, R., Roach, M., 3^rd, Phillips, T. Normal tissue dosimetric comparison between HDR prostate implant boost and conformal external beam radiotherapy boost: potential for dose escalation. Int J Radiat Oncol Biol Phys 46(4): 851-8, 2000.

Chou, R.H., Wilder, R.B., Ji, M., Ryu, J.K., Leigh, B.R., Earle, J.D., Doggett, R.L., Kubo, H.D., Roach, M., 3^rd, deVere White, R.W. Acute toxicity of three-dimensional conformal radiotherapy in prostate cancer patients eligible for implant monotherapy. Int J Radiat Oncol Biol Phys 47(1): 115-119, 2000.

Le, Q-T., Weinberg, V., Ryu, J., Lewis, P., Roach, M., 3^rd, An Analysis of Patients with Clinically Localized High-Risk Prostate Carcinoma. The Prostate Journal 2(3): 146-156, 2000.

Roach, M., 3^rd, Lu, J, Pilepich, M, et al. Four Prognostic Groups Predicting Long- Term Survival From Prostate Cancer Following Radiotherapy Alone On Radiation Therapy Oncology Group Clinical Trials. Int J Rad Onc Bio Phys 47 (3): 609-615, 2000.

Roach, M., 3^rd, Lu, J, Pilepich, M et al. Predicting Long Term Survival, and the Need for Hormonal Therapy: A Meta-Analysis of RTOG Prostate Cancer Trials. Int J Radiat Oncol Bio Phys 47 (3): 617- 627, 2000.

Goharderakhshan, R., Grossfeld, G., Kassis, A., Shinohara, K., Roach, M., 3^rd, Carroll, P. Additional Treatments and Reimbursement Rates Associated With Prostate Cancer Treatment for Patients Undergoing Radical Prostatectomy, Interstitial Brachytherapy, and External Beam Radiotherapy. Urology 56(4): 622-626, 2000.

Speight, J.L., Shinohara, K., Pickett, B., Weinberg, V.K., Hsu, I.C., Roach, M., 3^rd, Prostate Volume Change After Seed Implantation: Possible benefit of Improved Volume Histogram with Perioperative Steroid. Int J Radiat Oncol Biol Phys 48(5): 1461-1467, 2000.

Campbell, T., Blasko, J., Crawford, D., Forman, J., Hanks, G., Kuban, D., Montie, J., Moul, J., Pollack, A., Raghavan, D., Ray, P., Roach, M., 3^rd, et al. Clinical Staging of Prostate Cancer: Reproducibility and Clarification of Issues. Int J Cancer (Radiat. Oncol. Invest.): 96:2001.

Xia. P., Pickett, B., Vigneault, E., Verhey, L., Roach, M., 3^rd, Forward or inversely planned segmental multileaf collimator IMRT and sequential tomotherapy to treat multiple dominant intraprostatic lesions of prostate cancer to 90 Gy. Int J Radiat Oncol Biol Phys 2001; 51(1):244-54.

Shu, H. K. G., T. T. Lee, Vigneault E., Xia, P., Pickett, B., Phillips, T.L., Roach, M., 3^rd, Toxicity following high-dose three-dimensional conformal and intensity-modulated radiation therapy for clinically localized prostate cancer. Urology 57(1): 102-107, 2001.

Fisch, B., Pickett, B., Weinberg, V., Roach, M., 3^rd, Dose of Radiation Received by the Bulb of the Penis Correlates with Risk of Impotence After Three-Dimensional Conformal Radiotherapy for Prostate Cancer. Urology 57(5): 955-959, 2001.

Coakley FV, Hricak H, Wefer AE, Speight JL, Kurhanewicz J, Roach, M., 3^rd, Brachytherapy for prostate cancer: Endorectal MR imaging of local treatment-related changes. Radiology 2001; 219(3): 817-21.

Boyer, AL, Butler, EB, Dipetrillo, TA, Engler, MJ, Frass, B, Grant, W, Ling, CC, Low, DA, Mackie, TR, Mohan, R, Purdy JA, Roach, M., 3^rd, Rosenman, JG, Verhey, L, Wong, JW. Intensity-Modulated Radiotherapy: Current Status and Issues of Interest. Intensity Modulated Radiation Therapy Collaborative Working Group. Int. J Radiat Oncol Biol Phys. 51: 880-914, 2001.

Roach, M, Kurhanewicz, J, Carroll, P. Spectroscopy in Prostate Cancer: Hope or Hype? Oncology 15:1399-1410, 2001.

Jani, A.B., Vaida, F., Hanks, G.E., Asbell, S.O., Sartor, O., Moul, J., Roach, M., 3^rd, Brachman, D., Kalokhe, U., Muller-Runkel, R., Ray, P., Ignacio, L., Awan, A., Weiscelbaum, R., Vijayakumar, S. Changing face and different countenances of prostate cancer: Racial and geographic differences in prostate-specific antigen (PSA), stage, and grade trends in the PSA era. Int J Cancer 96: 363-371, 2001.

Pirzkall A, Carol MP, Pickett B, Xia P, Roach, M., 3^rd, Verhey LJ. The effect of beam energy and number of fields on photon-based IMRT for deep-seated targets. Int J Radiat Oncol Biol Phys 2002; 53(2): 434-42.

Shipley, W.U., Lu, J.D., Pilepich, M.V., Heydon, K., Roach, M., 3^rd, Wolkov, H.B., Sause, W.T., Rubin, P., Lawton, C.A., Machtay, M. The Effect of a Short Course of Neoadjuvant Hormone Treatment on the Response to Subsequent Androgen Suppression in Prostate Cancer Patients Who Relapse Following Radiation Therapy: A secondary analysis of the randomized protocol RTOG 86-10. Int J Radiat Oncol Biol Phys 54: 1302-10, 2002.

Lee TT, Everett DL, Shu HK, Jahan TM, Roach, M., 3^rd, Speight JL, et al. Radical pleurectomy/decortication and intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2002;124 (6):1183-9.

Lee WR, Roach, M., 3^rd, Michalski J, Moran B, Beyer D. Interobserver variability leads to significant differences in quantifiers of prostate implant adequacy. Int J Radiat Oncol Biol Phys 2002; 54(2): 457-61.

Michalski JM, Winter K, Purdy JA, Wilder R, Perez CA, Roach, M., 3^rd, et al. Trade-off to low-grade toxicity with conformal radiation therapy for prostate cancer on Radiation Therapy Oncology Group 9406. Semin Radiat Oncol 2002; 12(1 Suppl 1):75-80.

Ryu J.K., Winter K., Michalski J.M., Purdy J.A., Markoe A.M., Earle J.D., Perez, C.A., Roach, M., 3^rd, et al. Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 Gy). Int J Radiat Oncol Biol Phys; 54(4):1036-46, 2002.

Heron, D., Godette, K.D., Wynn, R.A., Arterbery, V.E., Streeter, O.A., Roach, M., 3^rd, et al. Radiation Medicine Innovations for the New Millenium. J Natl Med Assoc: 95(1): 55-63, 2003.

Michalski, J.M., Winter, K., Purdy, J.A., Wilder, R.B., Perez, C.A., Roach, M., 3^rd, et al. Preliminary evaluation of low grade toxicity with conformal radiation therapy for prostate cancer on RTOG 9406 dose levels I and II. Int J Radiat Oncol Biol Phys 56(1):192-198, 2003.

Roach, M., 3^rd, Lu, J., Pilepich M.V., Asbell, S.O., Mohiuddin, M., Grignon, D. Race and survival of men treated for prostate cancer on radiation therapy oncology group phase III randomized trials. J Urol 169 (1):245-250, 2003.

Roach, M., 3^rd, Weinberg, V., McLaughlin, P.W., Grossfeld, G., Sandler, H.M. Serum Prostate Specific Antigen (PSA) and Survival Following External Beam Radiotherapy for Carcinoma of the Prostate. Urology 61(4): 730-735, 2003.

Roach, M., 3^rd, DeSilvio, M., Lawton, C., Uhl, V., Machtay, M., Seider, M.J., Rotman, M., Jones, C., Asbell, S.O., Valicenti, R.K., Han, S., Thomas, C.R., Shipley, W.S. A Phase III Trial Comparing Whole Pelvic versus Prostate Only Radiotherapy and Neoadjuvant versus Adjuvant Combined Androgen Suppression: Radiation Therapy Oncology Group (RTOG) 9413. J Clin Oncol 21(10):1904-11, 2003.

Pouliot, J., Aubin, M., Langen, K.M., Liu, Y-M., Pickett, B., Shinohara, K., Roach, M., 3^rd, (Non)-Migration of Radio-opague Markers used for on-line Localization of the Prostate EPID. Int J Radiat Oncol Biol Phys 56(3): 862-866, 2003.

Takamiya, R., Weinberg, V., Young, C.D., McLaughlin, P., Sandler, H., Roach, M., 3^rd, A zero PSA slope in posttreatment prostate-specific antigen supports cure of patients with long-term follow-up after external beam radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2003; 56:1073-1078.

Bruner, D., Movsas, B., Konski, A., Roach, M., 3^rd, Bondy, M., Scarintino, C., Scott, C., Curran, W. Outcomes Research in Cancer Clinical Trial Cooperative Groups: The RTOG Model. (In Press, 2003).

DeWitt, K., Roach, M., 3^rd, Weinberg, V., McLaughlin, P., Sandler, H. What does postradiotherapy PSA nadir tell us about freedom from PSA failure and progression-free survival in patients with low and intermediate-risk localized prostate cancer? Urology 2003; 62:492-496.

Roach, M., 3^rd, Hormonal therapy and radiotherapy for localized prostate cancer: who, where and how long? J Urol 2003; 170:S35-40; discussion S40-31.

Langen, K.M., Pouliot, J., Anezinos, C., Aubin, M., Gottschalk, A.R., Hsu, I-C., Lowther, D., Liu, Y-M., Shinohara, K., Verhey, L., Weinberg, V., Roach, M., 3^rd, Evaluation of ultrasound-based prostate localization for image-guided radiotherapy. Int J Radiat Oncol Biol Phys 2003; 57: 635-644.

Chakravarti A, Heydon K, Wu CL, et al. Loss of p16 expression is of prognostic significance in locally advanced prostate cancer: an analysis from the Radiation Therapy Oncology Group protocol 86-10. J Clin Oncol 2003; 21: 3328-3334.

Scher HI, Eisenberger M, D'Amico AV, Halabi, S, Small, E. J., Morris, M., Kattan, M. W., Roach, M., 3^rd, et al. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 2004; 22:537-556.

Michalski JM, Winter K, Purdy JA Perez, C. A., Ryu, J. K., Parliament, M. B., Valicenti, R. K., Roach, M., 3^rd, et al. Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV. Int J Radiat Oncol Biol Phys 2004;58: 735-742.

Gottschalk AR, Roach, M., 3^rd, The use of hormonal therapy with radiotherapy for prostate cancer: analysis of prospective randomised trials. Br J Cancer 2004; 90:950-954.

Coakley, F. V., Teh, H. S., Qayyum, A., Swanson, M. G., Lu, Y., Roach, M., 3^rd, Pickett, B., Shinohara, K., Vigneron, D. B., Kurhanewicz, J. Endorectal MR imaging and MR spectroscopic imaging for locally recurrent prostate cancer after external beam radiation therapy: preliminary experience. Radiology 233 (2): 441-8, 2004.

Pickett, B., Haken, R.K, Kurhanewicz, J., Shinohara, K., Vigneron, D., Fein, B., Roach, M., 3^rd, Time Course to Metabolic Atrophy Following Permanent Prostate Seed Implantation Based on Magnetic Resonance Spectroscopic Imaging. Int J Radiat Oncol Biol Phys. 59:665-73, 2004.

Millender LE, Aubin M, Pouliot J, Shinohara K, Roach, M., 3^rd, Daily Electronic Portal Imaging for Morbidly obese Men Undergoing Radiotherapy for Localized Prostate Cancer. Int J Radiat Oncol Biol Phys. 59:6-10, 2004.

Zelefsky, M. J., Moughan, J., Owen, J., Zietman, A. L., Roach, M., 3^rd, Hanks, G. E. Changing trends in national practice for external beam radiotherapy for clinically localized prostate cancer: 1999 patterns of care survey for prostate cancer. Int J Radiat Oncol Biol Phys. 59:1053-61, 2004.

Roach, M., 3^rd, Reducing the toxicity associated with the use of radiotherapy in men with localized prostate cancer. Urol Clin North Am. 31: 353-66, 2004.

Pollack, A., DeSilvio, M., Khor, L. Y., Li, R., Al-Saleem, T. I., Hammond, M. E., Venkatesan, V., Lawton, C. A., Roach, M., 3^rd, et al. Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02. J Clin Oncol. 22:2133-40, 2004.

Li, R., Heydon, K., Hammond, M. E., Grignon, D. J., Roach, M., 3^rd et al. Ki-67 staining index predicts distant metastasis and survival in locally advanced prostate cancer treated with radiotherapy: an analysis of patients in radiation therapy oncology group protocol 86-10. Clin Cancer Res. 10: 4118-24, 2004.

Roach, M., 3^rd, Winter K, Michalski JM, et al. Penile Bulb Dose and Impotence Following 3D Conformal Radiotherapy For Prostate Cancer on RTOG 9406: Findings from a Prospective Multi-institutional Phase I-II Dose Escalation Study. Int J Radiat Oncol Biol Phys. 60 (5): 1351-6, 2004.

Liu, Y-M., Ling, S., Langen, K.M., Shinohara, K., Weinberg, V., Roach, M., 3^rd, Prostate Movement during Simulation Resulting from Retrograde Urethrogram Compared with 'Natural' Prostate Movement. Int J Radiat Oncol Biol Phys. 60:470-5, 2004.

Pickett B, Kurhanewicz J, Coakley F, Shinohara K, Fein B, Roach, M., 3^rd, Use of Magnetic Resonance Imaging and Spectroscopy (MRSI) in the Evaluation of External Beam Radiation Therapy for Prostate Cancer. Int J Radiat Oncol Biol Phys. 60:1047-1055, 2004.

Andrews J, Roach, M., 3^rd, Integrating hormonal therapy with external-beam radiation and brachytherapy for prostate cancer. Oncology (Williston Park). Jan 2005;19(1):29-36; discussion 36, 39, 43-24.

Pouliot J, Bani-Hashemi A, Chen J, Svatos M, Ghelmansarai F, Mitschke M, Aubin M, Xia P, Morin O, Bucci K, Roach, M., 3^rd, Hernandez P, Zheng Z, Hristov D, Verhey L. Low-Dose Megavoltage Cone-Beam CT for Radiation Therapy. Int J Radiat Oncol Biol Phys (61(2): 238-246, 2005.

Michalski JM, Winter K, Purdy JA, Parliament M, Wong H, Perez CA, Roach, M., 3^rd, Bosch W, Cox J. Toxicity After Three-Dimensional Radiotherapy for Prostate Cancer on RTOG 9406 Dose Level V. Int J Radiation Oncology Biol Phys 62(3):706-713, 2005.

Morris DE, Emami B, Mauch PM, Konski, A. A., Tao, M. L., Ng, A. K., Klein, E. A., Mohideen, N., Hurwitz, M. D., Fraas, B. A., Roach, M., 3^rd, Gore, E. M., Tepper, J. E.et al. Evidence-based review of three-dimensional conformal radiotherapy for localized prostate cancer: an ASTRO outcomes initiative. Int J Radiat Oncol Biol Phys. May 1 2005; 62(1):3-19.

Hartsell WF, Scott CB, Bruner DW, Scarantino CW, Ivker RA, Roach, M., 3^rd, et al. Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst. Jun 1 2005; 97 (11):798-804.

Bucci MK, Bevan A, Roach, M., 3^rd, Advances in radiation therapy: conventional to 3D, to IMRT, to 4D, and beyond. CA Cancer J Clin. Mar-Apr 2005; 55(2):117-134.

Speight, J.L., Roach, M., 3^rd, Radiotherapy in the Management of Clinically Localized Prostate Cancer: Evolving Standards, Consensus, Controversies and New Directions. 23:8176-85, 2005.

Shipley WU, Desilvio M, Pilepich MV, Roach, M., 3rd, et al. Early initiation of salvage hormone therapy influences survival in patients who failed initial radiation for locally advanced prostate cancer: A secondary analysis of RTOG protocol 86-10. Int J Radiat Oncol Biol Phys 64:1162-7, 2006. 

Pickett B, Kurhanewicz J, Pouliot J, Weinberg, V., Shinohara, K., Coakley, F., Roach, M., 3rd, et al. Three-dimensional conformal external beam radiotherapy compared with permanent prostate implantation in low-risk prostate cancer based on endorectal magnetic resonance spectroscopy imaging and prostate-specific antigen level. Int J Radiat Oncol Biol Phys 65:65-72, 2006. 

Abdel-Wahab M, Berkey BA, Krishan, A, O'Brien, T., Hammond, E., Roach, M., 3^rd, et al. Influence of number of CAG repeats on local control in the RTOG 86-10 protocol. Am J Clin Oncol 29: 14-20, 2006. 

Willoughby TR, Kupelian PA, Pouliot J, Shinohara K, Aubin M, Roach, M., 3^rd, Skrumeda LL, Balter JM, Litzenberg DW, Hadley SW, Wei JT, Sandler HM.  Target localization and real-time tracking using the Calypso 4D localization system in patients with localized prostate cancer.  Int J Radiat Oncol Biol Phys 65 (2)p: 528-534, 2006.

Roach, M., 3^rd, Hanks G, Thames Jr .H, Schellhammer P, Shipley WU, Sokol GH, Sandler H.  Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference.  Int J Radiat Oncol Biol Phys 65(4): 965-974, 2006. 

Aubin, M., Morin, O., Chen, J., Gillis, A., Pickett, B., Aubry, J. F., Akazawa, C., Speight, J., Roach, M., 3^rd, Pouliot, J. The use of megavoltage cone-beam CT to complement CT for target definition in pelvic radiotherapy in the presence of hip replacement. Br J Radiol 79:918-921, 2006. 

Wang-Chesebro, A., Xia, P., Coleman, J., Akazawa, C., Roach, M., 3^rd, IMRT Improves Lymph Node Coverage and Dose to Critical Structures Compared with 3D Conformal Radiation Therapy in Clinically Localized Prostate Cancer. Int J Radiat Oncol Biol Phys 66:654-662, 2006. 

Roach, M., 3^rd, DeSilvio, M., Valicenti, R., Grignon, D., Asbell S.O., Lawton, C., Thomas, C.R., Shipley, W.  Whole Pelvic, “Mini-Pelvic” or Prostate Only External Beam Radiotherapy following Neoadjuvant and Concurrent Hormonal Therapy (NHT) in Patients Treated on RTOG 9413. Int J Radiat Oncol Biol Phys 66:647-653, 2006. 

Roach, M., 3^rd, Weinberg, V., Nash M., Sandler, H.M., McLaughlin P.W., Kattan M. W. Defining High Risk Prostate Cancer with Risk Groups and Nomograms: Implications for Designing Clinical Trials.  J Urol Vol. 176, 2006. 

Morin, O., Gillis, A., Chen, J., Aubin, M., Bucci, M. K., Roach, M., 3^rd, Pouliot, J. Megavoltage cone-beam CT: system description and clinical applications.  Med Dosim 31:51-61, 2006. 

Ludlum E, Mu G, Weinberg V, Roach M, 3rd, Verhey LJ, Xia P. An algorithm for shifting MLC shapes to adjust for daily prostate movement during concurrent treatment with pelvic lymph nodes. Med Phys. Dec 2007;34(12):4750-4756.

Stone NN, Potters L, Davis BJ, et al. Customized dose prescription for permanent prostate brachytherapy: insights from a multicenter analysis of dosimetry outcomes. Int J Radiat Oncol Biol Phys. Dec 1 2007;69(5):1472-1477.

Litzenberg DW, Willoughby TR, Balter JM, et al. Positional Stability of Electromagnetic Transponders Used for Prostate Localization and Continuous, Real-Time Tracking. Int J Radiat Oncol Biol Phys. May 18 2007.

Speight JL, Roach, M., 3^rd, Advances in the treatment of localized prostate cancer: the role of anatomic and functional imaging in men managed with radiotherapy. J Clin Oncol. Mar 10 2007;25(8):987-995. 

Lee B, Shinohara K, Weinberg V, et al. Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: The University of California-San Francisco experience. Int J Radiat Oncol Biol Phys. Mar 15 2007;67(4):1106-1112. 

Schiffner DC, Gottschalk AR, Lometti M, et al. and Roach, M., 3^rd, Daily electronic portal imaging of implanted gold seed fiducials in patients undergoing radiotherapy after radical prostatectomy. Int J Radiat Oncol Biol Phys. Feb 1 2007;67(2):610-619.

Sahgal A, Roach, M., 3^rd, Permanent prostate seed brachytherapy: a current perspective on the evolution of the technique and its application. Nat Clin Pract Urol. Dec 2007;4(12):658-670.

Roach, M., 3^rd, Weinberg V, Sandler H, Thompson I. Staging for prostate cancer: time to incorporate pretreatment prostate-specific antigen and Gleason score? Cancer. Jan 15 2007;109(2):213-220. 

Roach, M., 3^rd, De Silvio M, Rebbick T, et al. Racial differences in CYP3A4 genotype and survival among men treated on Radiation Therapy Oncology Group (RTOG) 9202: a phase III randomized trial. Int J Radiat Oncol Biol Phys. Sep 1 2007;69(1):79-87. 

Frank SJ, Grimm PD, Sylvester JE, et al. Interstitial implant alone or in combination with external beam radiation therapy for intermediate-risk prostate cancer: a survey of practice patterns in the United States. Brachytherapy. Jan-Mar 2007;6(1):2-8.

Zapotoczna A, Sasso G, Simpson J, Roach, M., 3^rd, Current role and future perspectives of magnetic resonance spectroscopy in radiation oncology for prostate cancer. Neoplasia. Jun 2007;9(6):455-463. 

Lometti MW, Thurston D, Aubin M, …and Roach, M., 3^rd, Are lateral electronic portal images adequate for accurate on-line daily targeting of the prostate? Results of a prospective study. Med Dosim. Spring 2008;33(1):22-29.

Lawton CA, DeSilvio M, Roach, M., 3^rd, et al. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions.  Int J Radiation Oncol Biol Phys. 69(3):464-55, 2007. 

Roach, M., 3^rd, Bae K, Speight J, et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol. Feb 1 2008;26(4):585-591. 

D'ambrosio DJ, Pollack A, Harris EER, Price RA, Verhey LJ, Roach, M., 3^rd, Demanes DJ, Steinberg ML, Potters L, Wallern PE, Konski A.  Assessment of external beam radiation technology for dose escalation and normal tissue protection in the treatment of prostate cancer.  Int J Radiation Oncol Biol Phys.  70 (3):671-77, 2008.

McKenna DA, Coakley FV, Westphalen AC, et al. Prostate Cancer: Role of Pretreatment MR in Predicting Outcome after External-Beam Radiation Therapy-Initial Experience. Radiology. Feb 7 2008.

Shinohara K, Roach, M., 3^rd, Technique for implantation of fiducial markers in the prostate. Urology. Feb 2008;71(2):196-200. 

Chan LW, Xia P, Gottschalk AR, et al. and Roach, M., 3^rd,  Proposed Rectal Dose Constraints for Patients Undergoing Definitive Whole Pelvic Radiotherapy for Clinically Localized Prostate Cancer. Int J Radiat Oncol Biol Phys. Mar 12 2008. 

Chung HT, Xia P, Chan LW, Park-Somers E, and Roach, M., 3^rd, Does Image-Guided Radiotherapy Improve Toxicity Profile in Whole Pelvic-Treated High-Risk Prostate Cancer? Comparison Between IG-IMRT and IMRT. Int J Radiat Oncol Biol Phys. May 21 2008.